☆ 4.3 Meeting Abstract

A PROSPECTIVE PHASE II, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF SEG101 (CRIZANLIZUMAB) IN SICKLE CELL DISEASE PATIENTS WITH PRIAPISM (SPARTAN)

JOURNAL OF SEXUAL MEDICINE (2020)

Get Full Text
Add to Collection

Journal

JOURNAL OF SEXUAL MEDICINE
Volume 17, Issue 1, Pages S43-S43

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.jsxm.2019.11.092

Keywords

-

Categories

Urology & Nephrology

Funding

  1. Novartis Pharmaceutical Company

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.